0001558370-24-001305.txt : 20240216 0001558370-24-001305.hdr.sgml : 20240216 20240216161031 ACCESSION NUMBER: 0001558370-24-001305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEON Biopharma, Inc. CENTRAL INDEX KEY: 0001837607 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 853940478 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40021 FILM NUMBER: 24648429 BUSINESS ADDRESS: STREET 1: 5 PARK PLAZA STREET 2: SUITE 1750 CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: (949) 354-6499 MAIL ADDRESS: STREET 1: 5 PARK PLAZA STREET 2: SUITE 1750 CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: Priveterra Acquisition Corp. DATE OF NAME CHANGE: 20201222 8-K 1 aeon-20240214x8k.htm 8-K
0001837607false0001837607us-gaap:WarrantMember2024-02-142024-02-140001837607us-gaap:CommonStockMember2024-02-142024-02-1400018376072024-02-142024-02-14

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2024

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

​

Delaware

    

001-40021

    

85-3940478

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

​

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

    

Trading Symbol

    

Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share

​

AEON

​

NYSE American

Warrants to purchase Class A common stock

​

AEON WS

​

NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

​

​

​

Item 4.02. Non-Reliance on Previously Issued Financial Statements and Completed Interim Review.

Restatement of Historical Financial Results

On February 14, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of AEON Biopharma, Inc. (the “Company”), based on the recommendation of, and after consultation with, the Company’s management, concluded that the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2023, included in the Company’s Quarterly Report on Form 10-Q filed on November 13, 2023 (the “Form 10-Q”) and its Registration Statement on Form S-1 (File No. 333-274094) filed on November 24, 2023 (as amended, the “Registration Statement”), should no longer be relied upon due to certain errors identified. Similarly, any previously furnished or filed reports, related earnings releases, investor presentations or similar communications describing the Company’s financial results for the quarter ended September 30, 2023 should no longer be relied upon. The Company's management and the Audit Committee have discussed the matters described herein with KPMG LLP, the Company's independent registered public accounting firm. The identified errors had no impact on the Company’s cash balances or operating cash flows for the quarter ended September 30, 2023. Capitalized terms used but not defined in this Current Report on Form 8-K (this “Form 8-K”) have the meanings set forth in the Form 10-Q.

The following summarizes the nature and effect of the identified errors:

●Certain valuation estimates related to the fair value of the contingent consideration liability, convertible notes, stock-based compensation expense, and derivative liabilities were incorrectly calculated. These errors resulted in non-cash corrections to increase the loss reported on the Company’s condensed consolidated statements of operations and comprehensive loss for the Predecessor Period (July 1, 2023 to July 21, 2023) and the Predecessor Period (January 1, 2023 to July 21, 2023) by approximately $22.7 million; and an increase to the income reported on the Company’s condensed consolidated statements of operations and comprehensive loss for the Successor Period (July 22, 2023 to September 30, 2023) by approximately $6.4 million. The impact to correct these items on the Company’s condensed consolidated balance sheet at September 30, 2023 is expected to increase the contingent consideration liability by approximately $6.7 million.
●Certain errors related to items associated with the Merger that resulted in the reclassification of amounts between additional paid-in capital and accumulated deficit in the Successor’s condensed consolidated balance sheet.

The Company is still evaluating certain other non-cash items associated with the Merger and further revisions may be required. The Company expects to report one or more material weaknesses as a result of the errors identified, which would be in addition to the previously identified material weakness related to Priveterra’s ineffective internal controls as disclosed in the Form 10-Q. Any material weaknesses and the errors identified will be described in an Explanatory Note to an amendment to the Form 10-Q (the “Form 10-Q Amendment”). The Company intends to file restated unaudited interim financial statements in the Form 10-Q Amendment with the above stated corrections as soon as practicable.

​

Additionally, in accordance with ASC 205-40, Presentation of Financial Statements–Going Concern, the Company is required to make an assessment as of the date the restated financial statements are issued, regarding whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of amended filings. The Company expects to continue to report that there is substantial doubt about its ability to continue as a going concern as of the date of the respective amended filings. Based upon currently available information, the Company also anticipates that it will be disclosing that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the expected issuance date of the Form 10-K for the fiscal year ended December 31, 2023.

​

​

Cautionary Note Regarding Forward-Looking Statements.

Certain statements in this Form 8-K may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and include, for example, statements regarding the effects of the restatement of the Company’s past financial statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

 

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management at the time such statements are made, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against the Company or others; (ii) the Company’s ability to continue to meet continued stock exchange listing standards; (iii) costs related to being a public company; and (iv) other risks and uncertainties set forth in the sections entitled “Risk Factors” and

“Cautionary Note Regarding Forward-Looking Statements” in the Company’s prospectus and in subsequent filings with the Securities and Exchange Commission. Nothing in this Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not undertake any duty to update these forward-looking statements.

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

AEON Biopharma, Inc.

Date: February 16, 2024

By:

/s/ Marc Forth

​

​

Marc Forth

​

​

Chief Executive Officer

​

​

​

 EX-101.SCH 2 aeon-20240214.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 aeon-20240214_def.xml EX-101.DEF EX-101.LAB 4 aeon-20240214_lab.xml EX-101.LAB EX-101.PRE 5 aeon-20240214_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 14, 2024
Document Type 8-K
Document Period End Date Feb. 14, 2024
Entity File Number 001-40021
Entity Registrant Name AEON Biopharma, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-3940478
Entity Address State Or Province CA
Entity Address, Address Line One 5 Park Plaza
Entity Address, Adress Line Two Suite 1750
Entity Address, City or Town Irvine
Entity Address, Postal Zip Code 92614
City Area Code 949
Local Phone Number 354-6499
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001837607
Amendment Flag false
Common Stock [Member]  
Title of 12(b) Security Class A Common Stock, $0.0001 par value per share
Trading Symbol AEON
Security Exchange Name NYSEAMER
Warrant [Member]  
Title of 12(b) Security Warrants to purchase Class A common stock
Trading Symbol AEON WS
Security Exchange Name NYSEAMER
XML 7 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document Information
Feb. 14, 2024
Document Information:  
Document Type 8-K
Amendment false
CIK 0001837607
Registrant Name AEON Biopharma, Inc.
Period End Date Feb. 14, 2024
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200 - Document - Document Information Sheet http://xbrl.sec.gov/dei/role/document/DocumentInformation Document Information Cover 2 false false All Reports Book All Reports aeon-20240214.xsd aeon-20240214_def.xml aeon-20240214_lab.xml aeon-20240214_pre.xml aeon-20240214x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aeon-20240214x8k.htm": { "nsprefix": "aeon", "nsuri": "http://www.aeonbiopharma.com/20240214", "dts": { "schema": { "local": [ "aeon-20240214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2014/extensible-enumerations.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023_def.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/rxp/2023/rxp-2023.xsd", "https://xbrl.sec.gov/snj/2023/snj-2023.xsd", "https://xbrl.sec.gov/snj/2023/snj-2023_def.xsd" ] }, "definitionLink": { "local": [ "aeon-20240214_def.xml" ] }, "labelLink": { "local": [ "aeon-20240214_lab.xml" ] }, "presentationLink": { "local": [ "aeon-20240214_pre.xml" ] }, "inline": { "local": [ "aeon-20240214x8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 70, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_2_14_2024_To_2_14_2024_LSM5_r47WkWCXsfbdf1cNA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "aeon-20240214x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_2_14_2024_To_2_14_2024_LSM5_r47WkWCXsfbdf1cNA", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "aeon-20240214x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/dei/role/document/DocumentInformation", "longName": "995200 - Document - Document Information", "shortName": "Document Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "Duration_2_14_2024_To_2_14_2024_LSM5_r47WkWCXsfbdf1cNA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "aeon-20240214x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "rxp_A": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "A", "crdr": "debit", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Amount", "terseLabel": "Amount" } } }, "auth_ref": [] }, "country_AllCountriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "AllCountriesDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Countries [Domain]", "terseLabel": "All Countries" } } }, "auth_ref": [] }, "rxp_AllGovernmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "AllGovernmentsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "All Governments [Member]", "terseLabel": "All Governments" } } }, "auth_ref": [] }, "rxp_AllProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "AllProjectsMember", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "All Projects [Member]", "terseLabel": "All Projects" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "terseLabel": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "rxp_Bonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Bonuses", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Bonuses", "terseLabel": "Bonuses" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "rxp_Cm": { "xbrltype": "conversionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Cm", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Currency Conversion Method", "terseLabel": "Curr. Conv. Method" } } }, "auth_ref": [] }, "rxp_Co": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Co", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Country", "terseLabel": "Country" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "rxp_CommunityAndSocial": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "CommunityAndSocial", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Community and Social Responsibility", "terseLabel": "Comm. Social Resp." } } }, "auth_ref": [] }, "rxp_CountryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "CountryAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Country [Axis]", "terseLabel": "Country:" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "rxp_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Dividends", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Dividends", "terseLabel": "Dividends" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "terseLabel": "Document Information", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "terseLabel": "All Entities", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/DocumentInformation" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "terseLabel": "Reporting Currency", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "rxp_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Fees", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Fees", "terseLabel": "Fees" } } }, "auth_ref": [] }, "rxp_GovernmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "GovernmentAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByGovernment" ], "lang": { "en-us": { "role": { "label": "Government [Axis]", "terseLabel": "Government:" } } }, "auth_ref": [] }, "rxp_Gv": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Gv", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Government", "terseLabel": "Govt." } } }, "auth_ref": [] }, "rxp_InfrastructureImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "InfrastructureImprovements", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Infrastructure Improvements", "terseLabel": "Infrastructure" } } }, "auth_ref": [] }, "rxp_K": { "xbrltype": "yesItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "K", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind", "terseLabel": "In-kind" } } }, "auth_ref": [] }, "rxp_Km": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Km", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "In-kind Value Calculation", "terseLabel": "In-kind Calc." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity:", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "rxp_M": { "xbrltype": "extractionMethodItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "M", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Extraction Method", "terseLabel": "Ext. Method" } } }, "auth_ref": [] }, "rxp_P": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "P", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payment Type", "terseLabel": "Type" } } }, "auth_ref": [] }, "rxp_PaymentsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByCategoryTable", "lang": { "en-us": { "role": { "label": "Payments by Category [Table]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PaymentsByGovernmentTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByGovernmentTable", "lang": { "en-us": { "role": { "label": "Payments by Government [Table]", "terseLabel": "Payments, by Government:" } } }, "auth_ref": [] }, "rxp_PaymentsByProjectTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsByProjectTable", "lang": { "en-us": { "role": { "label": "Payments by Project [Table]", "terseLabel": "Payments, by Project:" } } }, "auth_ref": [] }, "rxp_PaymentsDetailTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsDetailTable", "lang": { "en-us": { "role": { "label": "Payments Detail [Table]", "terseLabel": "Payments Detail:" } } }, "auth_ref": [] }, "rxp_PaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PaymentsLineItems", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject", "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Payments [Line Items]", "terseLabel": "Payments:" } } }, "auth_ref": [] }, "rxp_PmtAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "PmtAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Pmt [Axis]", "terseLabel": "#" } } }, "auth_ref": [] }, "rxp_Pr": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Pr", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Project", "terseLabel": "Project" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "rxp_ProductionEntitlements": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "ProductionEntitlements", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Production Entitlements", "terseLabel": "Prod. Entitlements" } } }, "auth_ref": [] }, "rxp_ProjectAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "ProjectAxis", "presentation": [ "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Project [Axis]", "terseLabel": "Project:" } } }, "auth_ref": [] }, "rxp_R": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "R", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Resource", "terseLabel": "Resource" } } }, "auth_ref": [] }, "rxp_Royalties": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Royalties", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Royalties", "terseLabel": "Royalties" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "rxp_Sg": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Sg", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Segment", "terseLabel": "Segment" } } }, "auth_ref": [] }, "rxp_Sn": { "xbrltype": "enumerationItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Sn", "presentation": [ "http://xbrl.sec.gov/rxp/role/Detail" ], "lang": { "en-us": { "role": { "label": "Subnational Jurisdiction", "terseLabel": "Subnat. Juris." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "rxp_Taxes": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "Taxes", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": "rxp_TotalPayments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Taxes", "terseLabel": "Taxes" } } }, "auth_ref": [] }, "rxp_TotalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/rxp/2023", "localname": "TotalPayments", "crdr": "debit", "calculation": { "http://xbrl.sec.gov/rxp/role/ByCategory": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/rxp/role/ByCategory", "http://xbrl.sec.gov/rxp/role/ByGovernment", "http://xbrl.sec.gov/rxp/role/ByProject" ], "lang": { "en-us": { "role": { "label": "Total Payments", "terseLabel": "Total Payments" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001558370-24-001305-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-001305-xbrl.zip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end XML 17 aeon-20240214x8k_htm.xml IDEA: XBRL DOCUMENT 0001837607 us-gaap:WarrantMember 2024-02-14 2024-02-14 0001837607 us-gaap:CommonStockMember 2024-02-14 2024-02-14 0001837607 2024-02-14 2024-02-14 0001837607 false 8-K 2024-02-14 AEON Biopharma, Inc. DE 001-40021 85-3940478 5 Park Plaza Suite 1750 Irvine CA 92614 949 354-6499 false false false false Class A Common Stock, $0.0001 par value per share AEON NYSEAMER Warrants to purchase Class A common stock AEON WS NYSEAMER true false